Exploration of Neuroscience

Table 1. WHO 2021 classification: astrocytic tumors.

Astrocytic tumors
Diffuse astrocytoma	Astrocytoma, IDH-Mutant, Grade 2
	Astrocytoma, IDH-Mutant, Grade 3
	Astrocytoma, IDH-Mutant, Grade 4
	Glioblastoma Multiforme, IDH-Wildtype, Grade 4
Circumscribed astrocytoma	Pilocytic Astrocytoma
	High-Grade Astrocytoma with Piloid Features
	Pleomorphic Xanthoastrocytoma
	Subependymal Giant Cell Astrocytoma
	Chordoid Glioma
	Astroblastoma, MN1-altered

Return to article view

Data were adapted with permission of the Corresponding Author and Elsevier Book Publishers: Newton HB, Loughan AR. Chapter 8: Pathology and treatment of primary and metastatic brain tumors. In: Neuropsychological and Psychosocial Foundations of Neuro-Oncology. Elsevier; 2024. pp. 103–126.

Supplementary materials

The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/1006150_sup_1.pdf.

Declarations

Author contributions

HBN: Conceptualization, Writing—original draft, Writing—review & editing. BCA: Writing—original draft, Writing—review & editing. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, et al. Enabling Technologies for Personalized and Precision Medicine. Trends Biotechnol. 2020;38:497–518. [DOI] [PubMed] [PMC]

Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Adv Exp Med Biol. 2019;1168:9–30. [DOI] [PubMed]

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncol. 2015;17:1051–63. [DOI] [PubMed] [PMC]

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021;23:1231–51. [DOI] [PubMed] [PMC]

Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, et al. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro Oncol. 2023;25:813–26. [DOI] [PubMed] [PMC]

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29:1895–902. [DOI] [PubMed] [PMC]

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491–505. [DOI] [PubMed]

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The Somatic Genomic Landscape of Glioblastoma. Cell. 2013;155:462–77. [DOI] [PubMed] [PMC]

Li S, Wang C, Chen J, Lan Y, Zhang W, Kang Z, et al. Signaling pathways in brain tumors and therapeutic interventions. Signal Transduct Target Ther. 2023;8:8. [DOI] [PubMed] [PMC]

10.

Lemmon MA, Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. Cell. 2010;141:1117–34. [DOI] [PubMed] [PMC]

11.

Biarc J, Chalkley RJ, Burlingame AL, Bradshaw RA. Receptor tyrosine kinase signaling – a proteomic perspective. Adv Enzyme Regul. 2011;51:293–305. [DOI] [PubMed] [PMC]

12.

Newton HB. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anticancer Ther. 2014;3:595–614. [DOI] [PubMed]

13.

Newton HB. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy. 2nd ed. Academic Press; 2018.

14.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58. [DOI] [PubMed] [PMC]

15.

Cuesta C, Arévalo-Alameda C, Castellano E. The Importance of Being PI3K in the RAS Signaling Network. Genes (Basel). 2021;12:1094. [DOI] [PubMed] [PMC]

16.

Woods SA, Marmor E, Feldkamp M, Lau N, Apicelli AJ, Boss G, et al. Aberrant G protein signaling in nervous system tumors. J Neurosurg. 2002;97:627–42. [DOI] [PubMed]

17.

Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML. Blocking Ras inhibition as an antitumor strategy. Semin Cancer Biol. 2019;54:91–100. [DOI] [PubMed]

18.

Zubair T, Bandyopadhyay D. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. Int J Mol Sci. 2023;24:2651. [DOI] [PubMed] [PMC]

19.

Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules. 2022;27:819. [DOI] [PubMed] [PMC]

20.

Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253–75. [DOI] [PubMed]

21.

An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561–75. [DOI] [PubMed] [PMC]

22.

Qin A, Musket A, Musich PR, Schweitzer JB, Xie Q. Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter? Neurooncol Adv. 2021;3:vdab133. [DOI] [PubMed] [PMC]

23.

Habibi MA, Ahmadvand MH, Delbari P, Mirjani MS, Zare AH, Mehdizadeh B, et al. The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma. J Clin Neurosci. 2025;135:111138. [DOI] [PubMed]

24.

Ezzati S, Salib S, Balasubramaniam M, Aboud O. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities. Int J Mol Sci. 2024;25:2316. [DOI] [PubMed] [PMC]

25.

Chagoya G, Kwatra SG, Nanni CW, Roberts CM, Phillips SM, Nullmeyergh S, et al. Efficacy of osimertinib against EGFRvIII+ glioblastoma. Oncotarget. 2020;11:2074–82. [DOI] [PubMed] [PMC]

26.

Makhlin I, Salinas RD, Zhang D, Jacob F, Ming GL, Song H, et al. Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma. CNS Oncol. 2019;8:CNS43. [DOI] [PubMed] [PMC]

27.

Abousaud M, Faroqui NM, Lesser G, Strowd RE, Ramkissoon SH, Kwatra M, et al. Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations. J Cancer Sci Clin Ther. 2021;5:210–20. [DOI] [PubMed] [PMC]

28.

Cardona AF, Jaramillo-Velásquez D, Ruiz-Patiño A, Polo C, Jiménez E, Hakim F, et al. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol. 2021;154:353–64. [DOI] [PubMed]

29.

Hui C, Qu V, Wang JY, von Eyben R, Chang YC, Chiang PL, et al. Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. J Neurooncol. 2022;160:233–40. [DOI] [PubMed]

30.

Peled N, Kian W, Inbar E, Goldstein IM, Zemel M, Rotem O, et al. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Neurooncol Adv. 2021;4:vdab188. [DOI] [PubMed] [PMC]

31.

Solomón MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer. 2013;13:299. [DOI] [PubMed] [PMC]

32.

Du XJ, Li XM, Cai LB, Sun JC, Wang SY, Wang XC, et al. Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial. J Cancer. 2019;10:3214–23. [DOI] [PubMed] [PMC]

33.

Lin YJ, Mashouf LA, Lim M. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. Front Immunol. 2022;13:817296. [DOI] [PubMed] [PMC]

34.

Ravanpay AC, Gust J, Johnson AJ, Rolczynski LS, Cecchini M, Chang CA, et al. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 2019;10:7080–95. [DOI] [PubMed] [PMC]

35.

Subham S, Jeppson JD, Worcester C, Schatmeyer B, Zhao J, Madan R, et al. EGFR as a potent CAR T target in triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2023;197:57–69. [DOI] [PubMed] [PMC]

36.

Nazarenko I, Hede SM, He X, Hedrén A, Thompson J, Lindström MS, et al. PDGF and PDGF receptors in glioma. Ups J Med Sci. 2012;117:99–112. [DOI] [PubMed] [PMC]

37.

Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12:4899–907. [DOI] [PubMed]

38.

Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, et al. Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008;26:4659–65. [DOI] [PubMed] [PMC]

39.

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, et al. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). J Neurooncol. 2019;143:573–81. [DOI] [PubMed] [PMC]

40.

Sautter L, Hofheinz R, Tuettenberg J, Grimm M, Vajkoczy P, Groden C, et al. Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. Oncology. 2020;98:16–22. [DOI] [PubMed]

41.

Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol. 2005;16:1702–8. [DOI] [PubMed]

42.

Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Gururangan S, et al. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma. Cancer. 2012;118:4759–67. [DOI] [PubMed] [PMC]

43.

Krook MA, Reeser JW, Ernst G, Barker H, Wilberding M, Li G, et al. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2021;124:880–92. [DOI] [PubMed] [PMC]

44.

Lasorella A, Sanson M, Iavarone A. FGFR-TACC gene fusions in human glioma. Neuro Oncol. 2017;19:475–83. [DOI] [PubMed] [PMC]

45.

Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol. 2021;14:1233–52. [DOI] [PubMed]

46.

Lee EQ, Muzikansky A, Duda DG, Gaffey S, Dietrich J, Nayak L, et al. Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma. Cancer Med. 2019;8:5988–94. [DOI] [PubMed] [PMC]

47.

Sharma M, Schilero C, Peereboom DM, Hobbs BP, Elson P, Stevens GHJ, et al. Phase II study of Dovitinib in recurrent glioblastoma. J Neurooncol. 2019;144:359–68. [DOI] [PubMed]

48.

Wang Y, Liang D, Chen J, Chen H, Fan R, Gao Y, et al. Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3 - TACC3 Fusion and Recurrent Glioblastoma. Oncologist. 2021;26:173–7. [DOI] [PubMed] [PMC]

49.

Yang Q, Guo C, Lin X, Luo L, He Z, Lin F, et al. Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis. Front Pharmacol. 2021;12:804942. [DOI] [PubMed] [PMC]

50.

Liu C, Kuang S, Huang T, Wu J, Zhang L, Gong X. Radiotherapy plus temozolomide with or without anlotinib in H3K27M‐mutant diffuse midline glioma: A retrospective cohort study. CNS Neurosci Ther. 2024;30:e14730. [DOI] [PubMed] [PMC]

51.

Zhao S, Zhang M, Zhang Q, Wu J, Dai H. Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial. BMC Cancer. 2024;24:6. [DOI] [PubMed] [PMC]

52.

Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, et al. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022;28:2270–7. [DOI] [PubMed] [PMC]

53.

Capone S, Ketonen L, Weathers SP, Subbiah V. Activity of Pemigatinib in Pilocytic Astrocytoma and FGFR1^N546KMutation. JCO Precis Oncol. 2022;6:e2100371. [DOI] [PubMed] [PMC]

54.

Mabeta P, Steenkamp V. The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy. Int J Mol Sci. 2022;23:15585. [DOI] [PubMed] [PMC]

55.

Newton HB. Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors. Clin Med Therap. 2009;1:1577–97. [DOI]

56.

Al-Ostoot FH, Salah S, Khamees HA, Khanum SA. Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treat Res Commun. 2021;28:100422. [DOI] [PubMed]

57.

Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, Suksatan W, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022;20:49. [DOI] [PubMed] [PMC]

58.

Zhang T, Xin Q, Kang JM. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25:6480–91. [DOI] [PubMed]

59.

Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, et al. Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clin Cancer Res. 2008;14:7068–73. [DOI] [PubMed] [PMC]

60.

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol. 2023;41:4945–52. [DOI] [PubMed]

61.

Fu P, He YS, Huang Q, Ding T, Cen YC, Zhao HY, et al. Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 2016;4:833–8. [DOI] [PubMed] [PMC]

62.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma. N Engl J Med. 2014;370:709–22. [DOI] [PubMed]

63.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. N Engl J Med. 2014;370:699–708. [DOI] [PubMed] [PMC]

64.

Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, et al. Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. J Clin Oncol. 2010;28:2817–23. [DOI] [PubMed] [PMC]

65.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013;111:41–8. [DOI] [PubMed]

66.

Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45. [DOI] [PubMed] [PMC]

67.

Rivas S, Marín A, Samtani S, González-Feliú E, Armisén R. MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies. Int J Mol Sci. 2022;23:13898. [DOI] [PubMed] [PMC]

68.

Mulcahy EQX, Colόn RR, Abounader R. HGF/MET Signaling in Malignant Brain Tumors. Int J Mol Sci. 2020;21:7546. [DOI] [PubMed] [PMC]

69.

Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res. 2019;38:270. [DOI] [PubMed] [PMC]

70.

Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13:437–46. [DOI] [PubMed] [PMC]

71.

Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, et al. Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. Oncologist. 2018;23:889-e98. [DOI] [PubMed] [PMC]

72.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O⁶-Methylguanine–DNA Methyltransferase Biomarker Analyses. J Clin Oncol. 2017;35:343–51. [DOI] [PubMed]

73.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro-Oncol. 2018;20:259–67. [DOI] [PubMed] [PMC]

74.

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018;20:249–58. [DOI] [PubMed] [PMC]

75.

van den Bent M, Azaro A, De Vos F, Sepulveda J, Yung WKA, Wen PY, et al. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. J Neurooncol. 2020;146:79–89. [DOI] [PubMed] [PMC]

76.

Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018;175:1665–78.e18. [DOI] [PubMed]

77.

Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63:1523–37. [DOI] [PubMed] [PMC]

78.

Vaishnavi A, Le AT, Doebele RC. TRKing Down an Old Oncogene in a New Era of Targeted Therapy. Cancer Discov. 2015;5:25–34. [DOI] [PubMed] [PMC]

79.

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018;2018:1–20. [DOI] [PubMed] [PMC]

80.

Woo HY, Na K, Yoo J, Chang JH, Park YN, Shim HS, et al. Glioblastomas harboring gene fusions detected by next-generation sequencing. Brain Tumor Pathol. 2020;37:136–44. [DOI] [PubMed]

81.

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46:444–50. [DOI] [PubMed] [PMC]

82.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19:705–14. [DOI] [PubMed] [PMC]

83.

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–9. [DOI] [PubMed] [PMC]

84.

Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24:1776–89. [DOI] [PubMed] [PMC]

85.

Meredith DM, Cooley LD, Dubuc A, Morrissette J, Sussman RT, Nasrallah MP, et al. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients. Mod Pathol. 2023;36:100294. [DOI] [PubMed]

86.

Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987;84:9270–4. [DOI] [PubMed] [PMC]

87.

Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, et al. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res. 2018;24:6471–82. [DOI] [PubMed] [PMC]

88.

Richardson TE, Tang K, Vasudevaraja V, Serrano J, William CM, Mirchia K, et al. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. J Neuropathol Exp Neurol. 2019;78:1089–99. [DOI] [PubMed]

89.

Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020;37:569–83.e5. [DOI] [PubMed] [PMC]

90.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer. JCO Precis Oncol. 2017;2017:PO.17.00063. [DOI] [PubMed] [PMC]

91.

Dziadziuszko R, Hung T, Wang K, Choeurng V, Drilon A, Doebele RC, et al. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib. Mol Oncol. 2022;16:2000–14. [DOI] [PubMed] [PMC]

92.

Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2024;390:118–31. [DOI] [PubMed] [PMC]

93.

Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, et al. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer. Clin Cancer Res. 2021;27:2899–909. [DOI] [PubMed] [PMC]

94.

Mousa DV, Mavrovounis G, Argyropoulos D, Stranjalis G, Kalamatianos T. Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives. Cancers (Basel). 2024;16:650. [DOI] [PubMed] [PMC]

95.

Blandin AF, Giglio R, Graham MS, Garcia G, Malinowski S, Woods JK, et al. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clin Cancer Res. 2023;29:2651–67. [DOI] [PubMed] [PMC]

96.

Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A. Pleiotrophin Signaling through Anaplastic Lymphoma Kinase Is Rate-limiting for Glioblastoma Growth. J Biol Chem. 2002;277:14153–8. [DOI] [PubMed]

97.

Grzelinski M, Steinberg F, Martens T, Czubayko F, Lamszus K, Aigner A. Enhanced Antitumorigenic Effects in Glioblastoma on Double Targeting of Pleiotrophin and Its Receptor ALK. Neoplasia. 2009;11:145–56. [DOI] [PubMed] [PMC]

98.

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target? npj Precis Oncol. 2023;7:101. [DOI] [PubMed] [PMC]

99.

Franceschi E, De Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, et al. The clinical and prognostic role of ALK in glioblastoma. Pathol - Res Pract. 2021;221:153447. [DOI] [PubMed]

100.

Karagkounis G, Stranjalis G, Argyrakos T, Pantelaion V, Mastoris K, Rontogianni D, et al. Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome. J Clin Pathol. 2017;70:593–9. [DOI] [PubMed]

101.

Peyssonnaux C, Eychène A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53–62. [DOI] [PubMed]

102.

Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123–54. [DOI] [PubMed]

103.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med. 2011;364:2507–16. [DOI] [PubMed] [PMC]

104.

Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65. [DOI] [PubMed]

105.

Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, et al. Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 2016;370:332–44. [DOI] [PubMed]

106.

Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells. 2020;9:198. [DOI] [PubMed] [PMC]

107.

Cheng Y, Tian H. Current Development Status of MEK Inhibitors. Molecules. 2017;22:1551. [DOI] [PubMed] [PMC]

108.

Di Nunno V, Gatto L, Tosoni A, Bartolini S, Franceschi E. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. Front Oncol. 2023;12:1067252. [DOI] [PubMed] [PMC]

109.

Schreck KC, Grossman SA, Pratilas CA. BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. Cancers (Basel). 2019;11:1262. [DOI] [PubMed] [PMC]

110.

Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell. 2015;28:370–83. [DOI] [PubMed] [PMC]

111.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, et al. BRAF Inhibition in BRAF ^V600 -Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018;36:3477–84. [DOI] [PubMed] [PMC]

112.

Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30:207–17. [DOI] [PubMed] [PMC]

113.

van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martínez O, et al. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer. 2024;24:147. [DOI] [PubMed] [PMC]

114.

Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, et al. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014;5:5873–92. [DOI] [PubMed] [PMC]

115.

Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci. 2021;22:5850. [DOI] [PubMed] [PMC]

116.

Brosius S. A History of von Recklinghausen's NF1. J Hist Neurosci. 2010;19:333–48. [DOI] [PubMed]

117.

Rasmussen SA, Friedman JM. NF1 Gene and Neurofibromatosis 1. Am J Epidemiol. 2000;151:33–40. [DOI] [PubMed]

118.

Bollag G, McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 1991;351:576–9. [DOI] [PubMed]

119.

Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015;15:290–301. [DOI] [PubMed] [PMC]

120.

Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci. 2005;102:8573–8. [DOI] [PubMed] [PMC]

121.

Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y. Neurofibromin regulates G protein–stimulated adenylyl cyclase activity. Nat Neurosci. 2002;5:95–6. [DOI] [PubMed]

122.

Shapira S, Barkan B, Friedman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ. 2007;14:895–906. [DOI] [PubMed]

123.

Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, et al. The Neurofibromatosis Type 1 Gene Product Neurofibromin Enhances Cell Motility by Regulating Actin Filament Dynamics via the Rho-ROCK-LIMK2-Cofilin Pathway. J Biol Chem. 2005;280:39524–33. [DOI] [PubMed]

124.

Arima Y, Hayashi H, Kamata K, Goto TM, Sasaki M, Kuramochi A, et al. Decreased expression of neurofibromin contributes to epithelial–mesenchymal transition in neurofibromatosis type 1. Exp Dermatol. 2010;19:e136–41. [DOI] [PubMed]

125.

Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, et al. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Investig. 2012;122:3742–54. [DOI] [PubMed] [PMC]

126.

Laycock-van Spyk S, Thomas N, Cooper DN, Upadhyaya M. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. Hum Genomics. 2011;5:623–90. [DOI] [PubMed] [PMC]

127.

Patil S, Chamberlain RS. Neoplasms Associated with Germline and Somatic NF1 Gene Mutations. Oncologist. 2012;17:101–16. [DOI] [PubMed] [PMC]

128.

Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-Oncol. 2020;22:1527–35. [DOI] [PubMed] [PMC]

129.

Lobbous M, Bernstock JD, Coffee E, Friedman GK, Metrock LK, Chagoya G, et al. An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers (Basel). 2020;12:114. [DOI] [PubMed] [PMC]

130.

Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382:1430–42. [DOI] [PubMed] [PMC]

131.

Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, et al. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021;39:797–806. [DOI] [PubMed] [PMC]

132.

Moertel CL, Hirbe AC, Shuhaiber HH, Bielamowicz K, Sidhu A, Viskochil D, et al. ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma. J Clin Oncol. 2025;43:716–29. [DOI] [PubMed] [PMC]

133.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Immunity, Homeostasis, and Cancer. Annu Rev Cell Dev Biol. 2001;17:615–75. [DOI] [PubMed]

134.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. Cancer Res. 2008;68:6084–91. [DOI] [PubMed] [PMC]

135.

Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26. [DOI] [PubMed] [PMC]

136.

Li Z, Deng Z, Liu F, Li C, Yang K, Gong X, et al. Clinical sequencing reveals diagnostic, therapeutic, and prognostic biomarkers for adult-type diffuse gliomas. Heliyon. 2024;10:e37712. [DOI] [PubMed] [PMC]

137.

Brito C, Tomás A, Azevedo A, Esteves S, Mafra M, Roque L, et al. PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness. Clin Med Insights: Oncol. 2022;16:11795549211068804. [DOI] [PubMed] [PMC]

138.

Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2011;2:833–49. [DOI] [PubMed] [PMC]

139.

Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK. Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α. Proc Natl Acad Sci U S A. 2010;107:15547–52. [DOI] [PubMed] [PMC]

140.

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncol. 2018;20:66–77. [DOI] [PubMed] [PMC]

141.

Yu K, Lin CJ, Hatcher A, Lozzi B, Kong K, Huang-Hobbs E, et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature. 2020;578:166–71. [DOI] [PubMed] [PMC]

142.

Huang W, Hao Z, Mao F, Guo D. Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. Front Oncol. 2022;12:911876. [DOI] [PubMed] [PMC]

143.

Zhu J, Li K, Yu L, Chen Y, Cai Y, Jin J, et al. Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. Med Res Rev. 2021;41:1599–621. [DOI] [PubMed]

144.

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929–40. [DOI] [PubMed]

145.

Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, et al. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. Cancer Discov. 2017;7:704–15. [DOI] [PubMed] [PMC]

146.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. Ann Oncol. 2016;27:1928–40. [DOI] [PubMed] [PMC]

147.

Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, et al. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018;23:401-e38. [DOI] [PubMed] [PMC]

148.

Foster KA, Jane EP, Premkumar DR, Morales A, Pollack IF. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol. 2015;47:506–16. [DOI] [PubMed] [PMC]

149.

Speranza MC, Nowicki MO, Behera P, Cho CF, Chiocca EA, Lawler SE. BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma. Sci Rep. 2016;6:20189. [DOI] [PubMed] [PMC]

150.

Hanker AB, Kaklamani V, Arteaga CL. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discov. 2019;9:482–91. [DOI] [PubMed] [PMC]

151.

Cantley LC. The Phosphoinositide 3-Kinase Pathway. Science. 2002;296:1655–7. [DOI] [PubMed]

152.

Benitez JA, Ma J, D'Antonio M, Boyer A, Camargo MF, Zanca C, et al. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017;8:15223. [DOI] [PubMed] [PMC]

153.

Hill R, Wu H. PTEN, Stem Cells, and Cancer Stem Cells. J Biol Chem. 2009;284:11755–9. [DOI] [PubMed] [PMC]

154.

Drané P, Ouararhni K, Depaux A, Shuaib M, Hamiche A. The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 2010;24:1253–65. [DOI] [PubMed] [PMC]

155.

Lewis PW, Elsaesser SJ, Noh KM, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci. 2010;107:14075–80. [DOI] [PubMed] [PMC]

156.

Mendes-Pereira AM, Lord CJ, Ashworth A. NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells. PLoS ONE. 2012;7:e47249. [DOI] [PubMed] [PMC]

157.

Putz U, Howitt J, Doan A, Goh CP, Low LH, Silke J, et al. The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells. Sci Signal. 2012;5:ra70. [DOI] [PubMed]

158.

Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival. Science. 2013;341:399–402. [DOI] [PubMed] [PMC]

159.

Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone. Int J Cancer. 2006;118:2390–8. [DOI] [PubMed]

160.

Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, et al. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2011;130:73–83. [DOI] [PubMed]

161.

Li H, Liang Q, Wang L. Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL‐6/Stat3 pathway. J Cell Biochem. 2019;120:7257–64. [DOI] [PubMed]

162.

Xu B, Jiang C, Han H, Liu H, Tang M, Liu L, et al. Icaritin inhibits the invasion and epithelial‐to‐mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF‐1α signalling. Clin Exp Pharmacol Physiol. 2015;42:1296–307. [DOI] [PubMed]

163.

Ashrafizadeh M, Ahmadi Z, Mohammadinejad R, Ghasemipour Afshar E. Tangeretin: a mechanistic review of its pharmacological and therapeutic effects. J Basic Clin Physiol Pharmacol. 2020;31. [DOI] [PubMed]

164.

Elhag R, Mazzio EA, Soliman KF. The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Anticancer Res. 2015;35:1263–9. [PubMed] [PMC]

165.

Abadi AJ, Mirzaei S, Mahabady MK, Hashemi F, Zabolian A, Hashemi F, et al. Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res. 2022;36:189–213. [DOI] [PubMed]

166.

Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013;71:829–42. [DOI] [PubMed]

167.

Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69–94. [DOI] [PubMed]

168.

Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7:261–9. [DOI] [PubMed]

169.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science. 2005;307:1098–101. [DOI] [PubMed]

170.

Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling. Science. 2011;332:1317–22. [DOI] [PubMed] [PMC]

171.

Tripathy HK, Manju NSV, Dittakavi S, Zakkula A, Mullangi R. DBS Assay with LC-MS/MS for the Determination of Idelalisib, A Selective PI3K-δ Inhibitor in Mice Blood and Its Application to a Pharmacokinetic Study. Drug Res (Stuttg). 2021;71:36–42. [DOI] [PubMed]

172.

Bheemanaboina RRY. Isoform-Selective PI3K Inhibitors for Various Diseases. Curr Top Med Chem. 2020;20:1074–92. [DOI] [PubMed]

173.

Narkhede M, Cheson BD. Copanlisib in the treatment of non-Hodgkin lymphoma. Future Oncol. 2020;16:1947–55. [DOI] [PubMed]

174.

Xu PF, Yang JA, Liu JH, Yang X, Liao JM, Yuan FE, et al. PI3Kβ inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells. Oncol Rep. 2019;41:125–32. [DOI] [PubMed] [PMC]

175.

Briand J, Nadaradjane A, Bougras-Cartron G, Olivier C, Vallette FM, Cartron PF. Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation. Clin Epigenetics. 2019;11:159. [DOI] [PubMed] [PMC]

176.

Yesilöz Ü, Kirches E, Hartmann C, Scholz J, Kropf S, Sahm F, et al. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. Neuro-Oncol. 2017;19:1088–96. [DOI] [PubMed] [PMC]

177.

Knobbe CB, Reifenberger G. Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas. Brain Pathol. 2003;13:507–18. [DOI] [PubMed] [PMC]

178.

Gao L, Liu J, Xu P, Deng G, Liu B, Yuan F, et al. AKT Inhibitor SC66 Inhibits Proliferation and Induces Apoptosis in Human Glioblastoma Through Down-Regulating AKT/β-Catenin Pathway. Front Pharmacol. 2020;11:1102. [DOI] [PubMed] [PMC]

179.

Kolinsky MP, Rescigno P, Bianchini D, Zafeiriou Z, Mehra N, Mateo J, et al. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2020;31:619–25. [DOI] [PubMed] [PMC]

180.

Yamaji M, Ota A, Wahiduzzaman M, Karnan S, Hyodo T, Konishi H, et al. Novel ATP‐competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017;6:2646–59. [DOI] [PubMed] [PMC]

181.

Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex. Nature. 1994;369:756–8. [DOI] [PubMed]

182.

Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients. J Am Soc Nephrol. 2008;19:1411–8. [DOI] [PubMed] [PMC]

183.

Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, et al. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015;17:1275–83. [DOI] [PubMed] [PMC]

184.

Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. J Med Chem. 2017;60:7524–38. [DOI] [PubMed] [PMC]

185.

Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, et al. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020;26:1820–8. [DOI] [PubMed]

186.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, et al. NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 2015;367:58–68. [DOI] [PubMed]

187.

Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21:703. [DOI] [PubMed] [PMC]

188.

Lim-Fat MJ, Youssef GC, Touat M, Iorgulescu JB, Whorral S, Allen M, et al. Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2022;24:1140–9. [DOI] [PubMed] [PMC]

189.

Kim T, Lee A, Ahn S, Park JS, Jeun SS, Lee YS. Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation Sequencing. Brain Tumor Res Treat. 2024;12:23–39. [DOI] [PubMed] [PMC]

190.

Padovan M, Maccari M, Bosio A, De Toni C, Vizzaccaro S, Cestonaro I, et al. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis. Eur J Cancer. 2023;191:112959. [DOI] [PubMed]

191.

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21:39. [DOI] [PubMed] [PMC]

192.

Weller J, Potthoff AL, Zeyen T, Schaub C, Duffy C, Schneider M, et al. Current status of precision oncology in adult glioblastoma. Mol Oncol. 2024;18:2927–50. [DOI] [PubMed] [PMC]

193.

van den Bent MJ, Franceschi E, Touat M, French PJ, Idbaih A, Lombardi G, et al. Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection—Update 1. Neuro Oncol. 2025;27:331–7. [DOI] [PubMed] [PMC]

194.

Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 1991;10:1565–9. [DOI] [PubMed] [PMC]

195.

Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci CMLS. 1999;55:96–107. [DOI] [PubMed] [PMC]

196.

Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, et al. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996;15:5349–57. [PubMed] [PMC]

197.

Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein. J Biol Chem. 1999;274:38189–96. [DOI] [PubMed]

198.

Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222–31. [DOI] [PubMed]

199.

Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12. [DOI] [PubMed]

200.

Kaminska B, Czapski B, Guzik R, Król SK, Gielniewski B. Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins. Molecules. 2019;24:968. [DOI] [PubMed] [PMC]

201.

M Gagné L, Boulay K, Topisirovic I, Huot MÉ, Mallette FA. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. Trends Cell Biol. 2017;27:738–52. [DOI] [PubMed]

202.

Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580–9. [DOI] [PubMed] [PMC]

203.

Miller JJ. Targeting IDH-Mutant Glioma. Neurotherapeutics. 2022;19:1724–32. [DOI] [PubMed] [PMC]

204.

Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, et al. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma. J Clin Oncol. 2020;38:3398–406. [DOI] [PubMed] [PMC]

205.

Konteatis Z, Artin E, Nicolay B, Straley K, Padyana AK, Jin L, et al. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. ACS Med Chem Lett. 2020;11:101–7. [DOI] [PubMed] [PMC]

206.

Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA 3rd, Maher EA, Janku F, et al. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021;27:4491–9. [DOI] [PubMed] [PMC]

207.

Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023;29:615–22. [DOI] [PubMed] [PMC]

208.

Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389:589–601. [DOI] [PubMed] [PMC]

209.

de la Fuente MI, Colman H, Rosenthal M, Van Tine BA, Levacic D, Walbert T, et al. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial. Neuro-Oncol. 2022;25:146–56. [DOI] [PubMed] [PMC]

210.

Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463–8. [DOI] [PubMed] [PMC]

211.

Peng Y, Pei H. DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy. J Zhejiang Univ-SCI B. 2021;22:47–62. [DOI] [PubMed] [PMC]

212.

Yu W, Zhang L, Wei Q, Shao A. O6-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy. Front Oncol. 2020;9:1547. [DOI] [PubMed] [PMC]

213.

Gusyatiner O, Hegi ME. Glioma epigenetics: From subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50–8. [DOI] [PubMed]

214.

Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, et al. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020;2:vdaa082. [DOI] [PubMed] [PMC]

215.

Jiang S, Chai H, Tang Q, Shi Z, Zhou L. Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review. Discov Oncol. 2023;14:183. [DOI] [PubMed] [PMC]

216.

Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O⁶-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity. J Clin Oncol. 2008;26:4189–99. [DOI] [PubMed]

217.

Espinoza Pereira KN, Shan J, Licht JD, Bennett RL. Histone mutations in cancer. Biochem Soc Trans. 2023;51:1749–63. [DOI] [PubMed] [PMC]

218.

Jackson ER, Persson ML, Fish CJ, Findlay IJ, Mueller S, Nazarian J, et al. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered. Neuro-Oncol. 2024;26:S136–54. [DOI] [PubMed] [PMC]

219.

Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, et al. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. J Clin Oncol. 2024;42:1542–52. [DOI] [PubMed] [PMC]

220.

Pandit T, Ogden SK. Contributions of Noncanonical Smoothened Signaling During Embryonic Development. J Dev Biol. 2017;5:11. [DOI] [PubMed] [PMC]

221.

Espinosa-Bustos C, Mella J, Soto-Delgado J, Salas CO. State of the Art of Smo Antagonists for Cancer Therapy: Advances in the Target Receptor and New Ligand Structures. Future Med Chem. 2019;11:617–38. [DOI] [PubMed]

222.

Kong JH, Siebold C, Rohatgi R. Biochemical mechanisms of vertebrate hedgehog signaling. Development. 2019;146:dev166892. [DOI] [PubMed] [PMC]

223.

Jeng KS, Sheen IS, Leu CM, Tseng PH, Chang CF. The Role of Smoothened in Cancer. Int J Mol Sci. 2020;21:6863. [DOI] [PubMed] [PMC]

224.

Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5:1026–33. [DOI] [PubMed]

225.

Alexandre C, Jacinto A, Ingham PW. Transcriptional activation of hedgehog target genes in Drosophila is mediated directly by the cubitus interruptus protein, a member of the GLI family of zinc finger DNA-binding proteins.. Genes Dev. 1996;10:2003–13. [DOI] [PubMed]

226.

Denef N, Neubüser D, Perez L, Cohen SM. Hedgehog Induces Opposite Changes in Turnover and Subcellular Localization of Patched and Smoothened. Cell. 2000;102:521–31. [DOI] [PubMed]

227.

Mastronardi FG, Dimitroulakos J, Kamel-Reid S, Manoukian AS. Co-localization of Patched and activated Sonic hedgehog to lysosomes in neurons. NeuroReport. 2000;11:581–5. [DOI] [PubMed]

228.

Yauch RL, Dijkgraaf GJ, Alicke B, Januario T, Ahn CP, Holcomb T, et al. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma. Science. 2009;326:572–4. [DOI] [PubMed] [PMC]

229.

Chang L, Zhao D, Liu HB, Wang QS, Zhang P, Li CL, et al. Activation of sonic hedgehog signaling enhances cell migration and invasion by induction of matrix metalloproteinase-2 and -9 via the phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma. Mol Med Rep. 2015;12:6702–10. [DOI] [PubMed] [PMC]

230.

Khatua S, Song A, Citla Sridhar D, Mack SC. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Curr Neuropharmacol. 2018;16:1045–58. [DOI] [PubMed] [PMC]

231.

Ramaswamy V, Taylor MD. Medulloblastoma: From Myth to Molecular. J Clin Oncol. 2017;35:2355–63. [DOI] [PubMed]

232.

Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5:11. [DOI] [PubMed]

233.

Wang H, Lai Q, Wang D, Pei J, Tian B, Gao Y, et al. Hedgehog signaling regulates the development and treatment of glioblastoma (Review). Oncol Lett. 2022;24:294. [DOI] [PubMed] [PMC]

234.

Noman AS, Uddin M, Rahman MZ, Nayeem MJ, Alam SS, Khatun Z, et al. Overexpression of sonic hedgehog in the triple negative breast cancer: clinicopathological characteristics of high burden breast cancer patients from Bangladesh. Sci Rep. 2016;6:18830. [DOI] [PubMed] [PMC]

235.

Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W, et al. Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. Stem Cells. 2007;25:2524–33. [DOI] [PubMed] [PMC]

236.

Frampton JE, Basset-Séguin N. Vismodegib: A Review in Advanced Basal Cell Carcinoma. Drugs. 2018;78:1145–56. [DOI] [PubMed]

237.

Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel). 2016;8:22. [DOI] [PubMed] [PMC]

238.

Pereira V, Torrejon J, Kariyawasam D, Berlanga P, Guerrini-Rousseau L, Ayrault O, et al. Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma. Neurooncol Adv. 2021;3:vdab097. [DOI] [PubMed] [PMC]

239.

Kieran MW, Chisholm J, Casanova M, Brandes AA, Aerts I, Bouffet E, et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro-Oncol. 2017;19:1542–52. [DOI] [PubMed] [PMC]

240.

Sloan AE, Nock CJ, Ye X, Buerki R, Chang S, Lesser G, et al. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2022;161:33–43. [DOI] [PubMed] [PMC]

241.

Nanta R, Kumar D, Meeker D, Rodova M, Van Veldhuizen PJ, Shankar S, et al. NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis. 2013;2:e42. [DOI] [PubMed] [PMC]

242.

Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10:213. [DOI] [PubMed] [PMC]

243.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24:737–43. [DOI] [PubMed]

244.

Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, et al. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019;3:1–13. [DOI] [PubMed] [PMC]